Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Post-Mkt 09-18 18:23:33 EDT

110.29

-4.57

-3.98%

盘后111.57

+1.28+1.16%

17:48 EDT

High117.90	Low108.41	Vol17.23M
Open116.80	D1 Closing114.86	Amplitude8.26%
Mkt Cap11.92B	Tradable Cap10.64B	Total Shares108.10M
T/O1.90B	T/O Rate17.87%	Tradable Shares96.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":110.29,"timestamp":1789761600000,"preClose":114.86,"halted":0,"volume":17233208,"hourTrading":{"tag":"盘后","latestPrice":111.57,"preClose":110.29,"latestTime":"17:48 EDT","volume":4204908,"amount":463773600.0072,"timestamp":1789768106043,"change":1.28,"changeRate":0.011606,"amplitude":0.034736},"delay":0,"changeRate":-0.039787567473445876,"floatShares":96440095,"shares":108098397,"eps":0.453654,"marketStatus":"Post-Mkt","change":-4.57,"latestTime":"09-18 18:23:33 EDT","open":116.8,"high":117.9,"low":108.412,"amount":1903194304.1528802,"amplitude":0.082605,"askPrice":116.92,"askSize":100,"bidPrice":110.29,"bidSize":46,"shortable":3,"etf":0,"ttmEps":0.453654,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":114.86,"preHourTrading":{"tag":"盘前","latestPrice":116,"preClose":114.86,"latestTime":"09:28 EDT","volume":3161,"amount":365144.08457,"timestamp":1789738080087,"change":1.14,"changeRate":0.009925,"amplitude":0.009577},"postHourTrading":{"tag":"盘后","latestPrice":111.57,"preClose":110.29,"latestTime":"17:48 EDT","volume":4204908,"amount":463773600.0072,"timestamp":1789768106043,"change":1.28,"changeRate":0.011606,"amplitude":0.034736},"volumeRatio":15.598204,"impliedVol":0.4678,"impliedVolPercentile":0.2151},"requestUrl":"/m/hq/s/CORT/","defaultTab":"news","newsList":[{"id":"2668557927","title":"Corcept Therapeutics Price Target Maintained with a $165.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2668557927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668557927?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:50","pubTimestamp":1789750200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668273689","title":"Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668273689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668273689?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:30","pubTimestamp":1789749010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT) and Xenon (XENE) with bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4585","XENE","FBT","LABU","LU1559883803.SGD","BK4581","BK4532","LU0128526141.USD","BK4139","XLV","IBRN","CORT","LU0566484027.USD","PSCH","SBIO","HCSG","XBI","BK4137","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923679","title":"Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923679","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:01","pubTimestamp":1789732903,"startTime":"0","endTime":"0","summary":"Corcept says EU CHMP backs Lifyorli combo for platinum-resistant ovarian cancerEU drug regulator’s CHMP backed marketing authorization for Corcept’s Lifyorli (relacorilant) with nab-paclitaxel in plat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDLcd4Vr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","BK4007","FBT","PSCH","BK4532","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923688","title":"Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923688?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","FBT","PSCH","BK4532","BK4007","LU0566484027.USD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923684","title":"Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923684?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4532","PSCH","FBT","LU1559883803.SGD","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668693589","title":"Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668693589","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668693589?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:31","pubTimestamp":1789590707,"startTime":"0","endTime":"0","summary":"Corcept director James N. Wilson disposes of $1.11 million in common sharesCorcept director James N. Wilson reported selling 10,000 common shares on Sept. 15, 2026.Sales prices ranged from USD 110.27 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL5LXKps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSCH","LU0566484027.USD","LU1559883803.SGD","FBT","BK4532","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115350276","title":"S&P 500 to Add Bloom Energy, Illumina and Everpure in September Rebalance","url":"https://stock-news.laohu8.com/highlight/detail?id=1115350276","media":"Tiger Newspress","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115350276?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:27","pubTimestamp":1788564468,"startTime":"0","endTime":"0","summary":"S&P Dow Jones Indices will add $Bloom Energy(BE)$, $Everpure(P)$ and $Illumina(ILMN)$ to the S&P 500 as part of its quarterly index rebalance, with the changes taking effect before the U.S. market...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXTQ","BE","AXTL","BEG","DELL","HONA","PALD","BEX","SNDC","HRI","DK","SNDQ","P","ILMN","ATRC","PUL","AXTC","SPG","PANG","AXTI","CPRI","ARQT","HUBS","EAT","BEC","SNDK","TAP","AXTU","ANET","CL","BEZ","TTD","BLDR","AGNC","SNXX","SNDG","PANW","AXTX","ANEL","NKE","SAM","SNDU","TTDU","CORT","DLLL","PALU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800115","title":"Corcept Names Roberto Vieira as President, Oncology in Initial Beneficial Ownership Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800115","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800115?lang=en_us&edition=fundamental","pubTime":"2026-09-04 08:40","pubTimestamp":1788482411,"startTime":"0","endTime":"0","summary":"Corcept names Roberto Vieira as President, Oncology in initial beneficial ownership filingCorcept Therapeutics President, Oncology Roberto Wandenkolk Vieira disclosed 4,068 common shares in an initial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL3ZgV8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","FBT","PSCH","CORT","BK4532","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663011648","title":"Corcept Therapeutics Insider Makes Major Multimillion-Dollar Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2663011648","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663011648?lang=en_us&edition=fundamental","pubTime":"2026-08-29 10:06","pubTimestamp":1787969183,"startTime":"0","endTime":"0","summary":"New insider activity at Corcept Therapeutics ( ($CORT) ) has taken place on August 28, 2026. Director Park Kimberly has recently cashed out a signi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/corcept-therapeutics-insider-makes-major-multimillion-dollar-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/corcept-therapeutics-insider-makes-major-multimillion-dollar-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CORT","LU0566484027.USD","FBT","LU1559883803.SGD","BK4532","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033320","title":"Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033320","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033320?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:31","pubTimestamp":1787862696,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck disposes of 30,955 Corcept shares worth $3.88 millionCorcept Therapeutics President, Corcept Endocrinology Sean Maduck exercised stock options for 30,955 co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDLbYdy60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262741","title":"Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661262741?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:00","pubTimestamp":1787310037,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT), Alvotech (ALVO) and Abb...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-alvotech-alvo-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-alvotech-alvo-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","XBI","LU2211815571.USD","BK4568","LU0029874061.USD","FBT","LU0320765489.SGD","LU0211331839.USD","LU1721429402.USD","IE0009355771.USD","PJP","IE00BFTCPJ56.SGD","BK4592","LU0882574055.USD","BK4082","ALVO","LU2237957811.SGD","LU1721429741.USD","LU2324357040.USD","LU1559883803.SGD","LU0266013472.USD","LU0058720904.USD","SGXZ41872573.SGD","BK4581","LU0868494617.USD","LU2237957902.USD","ABT","LU0208291251.USD","LU2133065610.SGD","LABU","BK4137","LU2112291526.USD","LU0566484027.USD","LU0070302665.USD","PSCH","TMED","IHI","LU1023059063.AUD","XLV","BK4007","LU1914381329.SGD","IE00B2B36J28.USD","HCSG","SG9999002224.SGD","IE00B4R5TH58.HKD","BK4139","CORT","SG9999002232.USD","LU0234572021.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661129232","title":"Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661129232","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661129232?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:30","pubTimestamp":1787257853,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics director David L. Mahoney sells 103,606 shares worth $12.26 millionCorcept director David L. Mahoney sold 103,606 shares on Aug. 18.Sales priced at $117.47 to $119.64, weighted-av","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL759h51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4007","CORT","LU0566484027.USD","PSCH","LU1559883803.SGD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660371492","title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660371492","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660371492?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085063,"startTime":"0","endTime":"0","summary":"Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 millionCorcept Therapeutics Chief Business Officer Gary Charles Robb sold 10,000 common shares on Aug. 17.Sale priced at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLc47Ccv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","CORT","BK4532","LU0566484027.USD","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660619704","title":"Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2660619704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660619704?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:04","pubTimestamp":1787051049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","BK4007","CORT","LU1559883803.SGD","LU0566484027.USD","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469007","title":"Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469007?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:47","pubTimestamp":1787050049,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) has an average rating of overweight and mean price target of $141, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660445813","title":"Corcept Therapeutics Earnings Call Signals Accelerating Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2660445813","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660445813?lang=en_us&edition=fundamental","pubTime":"2026-08-18 08:15","pubTimestamp":1787012106,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (($CORT)) has held its Q2 earnings call. Read on for the main highlights of the call. Corcept Therapeutics’ latest earnings ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-earnings-call-signals-accelerating-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-earnings-call-signals-accelerating-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900794","title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900794","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900794?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:27","pubTimestamp":1786566428,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer disposes of common shares worth $1.85 millionCorcept disclosed Chief Development Officer William Guyer exercised options for 16,300 shares at $ 21.65 on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL2qSVvx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","BK4532","LU0566484027.USD","FBT","BK4007","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656597","title":"Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656597","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656597?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:39","pubTimestamp":1786030757,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics stock has delivered a very large 5 year return, yet its recent valuation checks suggest the shares are not an obvious bargain at today's level.\n\nOver the past 5 years, Corcept Therapeutics has returned about 4.4x, which sets a high bar for any further upside to be justified by fundamentals.\nInvestor focus is currently on how demand for the company’s treatments and late stage pipeline can support future revenue, while execution and clinical outcomes across those programs...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSCH","FBT","BK4007","LU1559883803.SGD","CORT","LU0566484027.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571260","title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571260","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571260?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:11","pubTimestamp":1785967865,"startTime":"0","endTime":"0","summary":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon disposes of 1,540 common shares worth $175,806.40Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon sold 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4ffvrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","CORT","FBT","LU1559883803.SGD","BK4007","LU0566484027.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544649","title":"We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544649","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544649?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:29","pubTimestamp":1785929370,"startTime":"0","endTime":"0","summary":"Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/we-think-that-there-are-more-issues-for-corcept-therapeutics","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/we-think-that-there-are-more-issues-for-corcept-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","CORT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0274},{"period":"3month","weight":0.4374},{"period":"6month","weight":2.3158},{"period":"1year","weight":0.5278},{"period":"ytd","weight":2.3006}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.048323},{"month":7,"riseRate":0.478261,"avgChangeRate":0.007526},{"month":8,"riseRate":0.391304,"avgChangeRate":-0.006443},{"month":9,"riseRate":0.478261,"avgChangeRate":0.060051},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}